乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨

doi:10.3969/j.issn.1674-8115.2022.12.013

上海交通大学学报（医学版） ›› 2022, Vol. 42 ›› Issue (12): 1745-1750.doi: 10.3969/j.issn.1674-8115.2022.12.013

• 综述 • 上一篇

乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨

张郁瑭¹(), 金奕婕¹, 张凤春², 徐迎春¹()

^1.上海交通大学医学院附属仁济医院肿瘤科，上海 200127
^2.上海交通大学医学院苏州九龙医院肿瘤科，苏州 215127

收稿日期:2022-06-24 接受日期:2022-09-04 出版日期:2022-12-28 发布日期:2022-12-28
通讯作者: 徐迎春 E-mail:553572892@qq.com;xiaoxu2384@163.com
作者简介:张郁瑭（1999—），男，本科生；电子信箱：553572892@qq.com。
基金资助:
国家自然科学基金(81301858);苏州市科技计划项目(SYS201404);江苏省自然科学基金(BK20181186)

Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

ZHANG Yutang¹(), JIN Yijie¹, ZHANG Fengchun², XU Yingchun¹()

^1.Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
^2.Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215127, China

Received:2022-06-24 Accepted:2022-09-04 Online:2022-12-28 Published:2022-12-28
Contact: XU Yingchun E-mail:553572892@qq.com;xiaoxu2384@163.com
Supported by:
National Natural Science Foundation of China(81301858);Suzhou Science and Technology Project(SYS201404);Natural Science Foundation of Jiangsu Province(BK20181186)

摘要/Abstract

摘要：

新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）作为一种新发的急性呼吸道传染病，目前已成为全球性重大公共卫生事件。在COVID-19流行期间，与健康人群相比，癌症患者因基础免疫力较差、年龄较大等特点，感染COVID-19后发生其他系统并发症的风险更高。研究显示，在女性恶性肿瘤中，乳腺癌的发病率位居第一。该类患者合并COVID-19感染的预后更差，且因COVID-19感染而不得不推迟抗肿瘤治疗。目前，关于推迟治疗对乳腺癌患者生存期的影响尚不明确，是否应调整这部分患者的治疗方案也仍处于研究中。该文通过系统回顾现有临床研究结果、各学会指南及专家共识，对COVID-19疫情下乳腺癌治疗方案的选择及合理化调整进行综述，探讨COVID-19感染的乳腺癌患者的抗肿瘤治疗时机和合理可行的抗肿瘤治疗方式。

关键词: 乳腺癌, 新型冠状病毒肺炎, 手术, 放射治疗, 系统治疗

Abstract:

Coronavirus disease 2019 (COVID-19) has become a major global public health event as a new acute respiratory infectious disease. During the COVID-19 pandemic, compared with the healthy population, cancer patients had a higher risk of developing comorbidities of other systems, due to their bad poor immunity and older age. Research showed that breast cancer, as a malignant disease, had the highest disease incidence in female patients. Breast cancer patients with COVID-19 infection often have worse prognosis, and they have to postpone anti-tumor treatment due to COVID-19 infection. At present, the effect of delayed treatment on the survival rate of breast cancer patients is unclear, and whether the treatment plan of these patients should be adjusted is still being studied. Through the systematic review of existing clinical research studies, the guidelines of various societies and the expert consensus, this paper reviews the selection and rationalization of breast cancer treatment options under the COVID-19 epidemic, and discusses the opportunity and approaches of anti-tumor treatment for breast cancer patients infected with COVID-19.

Key words: breast cancer, coronavirus disease 2019 (COVID-19), surgery, radiotherapy, systemic therapy

中图分类号:

R737.9

张郁瑭, 金奕婕, 张凤春, 徐迎春. 乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨[J]. 上海交通大学学报（医学版）, 2022, 42(12): 1745-1750.

ZHANG Yutang, JIN Yijie, ZHANG Fengchun, XU Yingchun. Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1745-1750.

图/表 1

参考文献 32

1	LIANG W H, GUAN W J, CHEN R C, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337.
2	TIAN J, YUAN X, XIAO J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre,
3	YU J, OUYANG W, CHUA M L K, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China[J]. JAMA Oncol, 2020, 6(7): 1108-1110.
4	ZHANG L, ZHU F, XIE L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901.
5	DAI M Y, LIU D B, LIU M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6): 783-791.
6	FOX T A, TROY-BARNES E, KIRKWOOD A A, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy[J]. Br J Haematol, 2020, 191(2): 194-206.
7	LEE L Y, CAZIER J B, ANGELIS V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study[J]. Lancet, 2020, 395(10241): 1919-1926.
8	PATHANIA A S, PRATHIPATI P, ABDUL B A, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges[J]. Theranostics, 2021, 11(2): 731-753.
9	JEE J, FOOTE M B, LUMISH M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer[J]. J Clin Oncol, 2020, 38(30): 3538-3546.
10	ROBILOTTI E V, BABADY N E, MEAD P A, et al. Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8): 1218-1223.
11	DE AZAMBUJA E, TRAPANI D, LOIBL S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000793.
12	黎立喜, 马飞. 《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读[J]. 中国肿瘤临床, 2020, 47(8): 379-383.
	LI L X, MA F. Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak[J]. Chin J Clin Oncol, 2020, 47(8): 379-383.
13	MARTA G N, POORTMANS P. Moderately hypofractionated breast radiation therapy: is more evidence needed? [J]. Lancet Oncol, 2019, 20(5): e226.
14	GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
15	WANG S L, FANG H, SONG Y W, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 352-360.
16	CURIGLIANO G, BANERJEE S, CERVANTES A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus[J]. Ann Oncol, 2020, 31(10): 1320-1335.
17	SULLIVAN R J, JOHNSON D B, RINI B I, et al. COVID-19 and immune checkpoint inhibitors: initial considerations[J]. J Immunother Cancer, 2020, 8(1): e000933.
18	DEEKS J J, DINNES J, TAKWOINGI Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2[J]. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
19	VAN KAMPEN J J A, VAN DE VIJVER D A M C, FRAAIJ P L A, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)[J]. Nat Commun, 2021, 12(1): 267.
20	RHEE C, KANJILAL S, BAKER M, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? [J]. Clin Infect Dis, 2021, 72(8): 1467-1474.
21	BULLARD J, DUST K, FUNK D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples[J]. Clin Infect Dis, 2020, 71(10): 2663-2666.
22	YU K D, FAN L, QIU L X, et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent[J]. Oncotarget, 2017, 8(28): 46549-46556.
23	胡夕春, 胡志皇, 王碧芸, 等. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.
	HU X C, HU Z H, WANG B Y, et al. COVID-19 and systemic anti-cancer therapy[J]. Chin Oncol, 2022, 32(6): 499-511.
24	WEI J L, WU M J, LIU J, et al. Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China[J]. Breast, 2021, 59: 102-109.
25	BERSANELLI M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(5): 269-273.
26	WU Q J, CHU Q, ZHANG H Y, et al. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors[J]. Cancer Commun (Lond), 2020, 40(8): 374-379.
27	LUO J, RIZVI H, EGGER J V, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers[J]. Cancer Discov, 2020, 10(8): 1121-1128.
28	LIÈVRE A, TURPIN A, RAY-COQUARD I, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)[J]. Eur J Cancer, 2020, 141: 62-81.
29	WANG B, HUANG Y. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis[J]. Oncoimmunology, 2020, 9(1): 1824646.
30	DI GIACOMO A M, GAMBALE E, MONTERISI S, et al. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: clinical course and outcome[J]. Eur J Cancer, 2020, 133: 1-3.
31	HU S Y, YIN F Y, NIE L T, et al. Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 829879.
32	SAINI K S, LANZA C, ROMANO M, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy[J]. Br J Cancer, 2020, 123(5): 694-697.

Type of therapy	Name of drug	Mechanism	NCT number
Chemotherapy	Methotrexate	Antimetabolite， DHFR inhibitor	NCT04352465
Target therapy	Palbociclib， abivertinib	CDK4/6 inhibitor	NCT05371275 NCT04440007
Immunotherapy	Nivolumab， pembrolizumab	PD-1inhibitor	NCT04356508 NCT04335305
Antiangiogenic therapy	Bevacizumab， nintedanib	VEGF inhibitor	NCT04275414 NCT04338802
Radiotherapy	/	Destroy DNA	NCT04366791

Type of therapy	Name of drug	Mechanism	NCT number
Chemotherapy	Methotrexate	Antimetabolite， DHFR inhibitor	NCT04352465
Target therapy	Palbociclib， abivertinib	CDK4/6 inhibitor	NCT05371275 NCT04440007
Immunotherapy	Nivolumab， pembrolizumab	PD-1inhibitor	NCT04356508 NCT04335305
Antiangiogenic therapy	Bevacizumab， nintedanib	VEGF inhibitor	NCT04275414 NCT04338802
Radiotherapy	/	Destroy DNA	NCT04366791

[1]	孙惠华, 田秋菊, 吴蓓雯. 不同气腹模式下腹腔镜手术患者下肢深静脉血流速度的比较[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1329-1335.
[2]	回文宇, 吴锦阳, 黄建华, 栾楠, 张志愿, 张诗雷. 机器人辅助颏成形术行截骨操作的精度评价实验研究[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1347-1352.
[3]	陶宝鑫, 蓝耕良, 黄伟, 王凤, 沈意涵, 吴轶群. 动态导航技术辅助无牙颌种植精度分析[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1353-1360.
[4]	夏坤健, 邓林林, 王琳. 乳腺癌化学治疗致肝损伤预测模型的构建及其评价[J]. 上海交通大学学报（医学版）, 2022, 42(4): 502-509.
[5]	苏俊澄, 王禹铮, 唐雷, 徐迎春, 张凤春. 乳腺癌脑转移患者的临床病理特征及预后的影响因素分析[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1562-1568.
[6]	孙亚蒙, 马晔, 郭润生. 乳腺癌组织样本中 HER2基因拷贝数的检测分析[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1589-1597.
[7]	王禹铮, 苏俊澄, 唐雷, 徐迎春, 张凤春. 单周紫杉醇联合顺铂一线治疗转移性乳腺癌的效果和安全性的回顾性研究[J]. 上海交通大学学报（医学版）, 2022, 42(10): 1420-1427.
[8]	陈炜, 刘颖斌. 肝门部胆管癌综合治疗的进展与争议[J]. 上海交通大学学报(医学版), 2022, 42(1): 1-8.
[9]	陈翠, 金叶, 王琳, 李红丽, 万财凤, 姜立新. 30例乳腺化生性癌的多种影像学对比分析[J]. 上海交通大学学报(医学版), 2022, 42(1): 70-76.
[10]	吉耿锋, 张志波. Ⅲ型胆道闭锁患儿肝门肠吻合术预后相关因素分析[J]. 上海交通大学学报(医学版), 2021, 41(9): 1142-1146.
[11]	周天浩, 辛肇晨, 杜少倩, 曹源, 许静轩, 劳曾红, 王红霞. 乳腺癌类器官共培养技术的建立和优化[J]. 上海交通大学学报(医学版), 2021, 41(8): 1017-1024.
[12]	季艳杰, 罗浩, 蔡海燕, 刘欣宇, 金诗佳, 粟深月, 徐含章, 雷虎, 吴英理. CDDO-Me对三阴性乳腺癌细胞泛素特异性蛋白酶2a活性及细胞增殖的抑制作用[J]. 上海交通大学学报(医学版), 2021, 41(8): 1025-1032.
[13]	周珺珺, 赵洁, 汤静燕, 蒋马伟, 马秀梅, 白永瑞. Ⅲ~Ⅳ期神经母细胞瘤患儿放射治疗预后因素分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1051-1055.
[14]	王子涵, 沈杰, 罗艳. 复合脊神经阻滞用于单孔胸腔镜下肺段/叶切除术的镇痛效果[J]. 上海交通大学学报(医学版), 2021, 41(8): 1062-1067.
[15]	钱文静, 章雅青. 手术室护士工作压力源量表的研制及信度和效度检验[J]. 上海交通大学学报(医学版), 2021, 41(8): 1081-1088.

乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨

Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 32

相关文章 15

编辑推荐

Metrics